ArticleCureus2026
Possible Diclofenac-Related Fulminant Toxic Epidermal Necrolysis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxic epidermal necrolysis (TEN) is a rare but life-threatening cutaneous adverse effect characterized by extensive epidermal detachment and systemic inflammation. Though anticonvulsants, sulfonamides, and allopurinol are most frequently associated with TEN, nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac have been involved in very few case reports. This case study presents a 76-year-old man with tophaceous gout who, after a self-administered single dose of 75 mg intramuscular diclofenac, developed fulminant TEN. At the time of hospital admission, the patient's skin showed progressively developing purpuric and bullous lesions covering 40.5% of the total body surface area, a positive Nikolsky sign, severe mucosal involvement, metabolic acidosis, acute kidney failure, thrombocytopenia, and multiorgan failure. Despite aggressive supportive care management, the patient died shortly after hospital admission. Based on the SCORe of Toxic Epidermal Necrosis (SCORTEN) severity score of 5, the patient was classified as having a very high risk of mortality, corresponding to an estimated mortality rate of approximately 85%. Using the Naranjo algorithm for evaluating the causal relationship between a drug therapy and a possible side effect, we obtained a score of 2, which points to a possible side effect, while the re-exposure to febuxostat, etoricoxib, and pregabalin was an alternate pharmacological variable during the course of the adverse event. This case highlights the potential for rapidly progressive and fatal TEN following recent NSAID exposure and underscores the importance of early recognition, prompt withdrawal of suspected medications, and careful causality assessment in patients receiving multiple drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.